Shares in Intra-Cellular Therapies rose sharply after it reported that its only product Caplyta was effective for a new indication, major depressive disorder (MDD), in a phase 3 trial. Caplyta ...
Johnson & Johnson has agreed to take over Intra-Cellular Therapies in a deal worth up to $14.6 billion – the second biopharma M&A announcement today. The $132-per-share agreement comes a few months ...
Correspondence to Professor Christian Kopkow, Department für Angewandte Gesundheitswissenschaften, Hochschule für Gesundheit (University of Applied Sciences), Gesundheitscampus 6–8, Bochum 44801, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback